WO2004104163A2 - α−選択的グリコシル化反応方法 - Google Patents
α−選択的グリコシル化反応方法 Download PDFInfo
- Publication number
- WO2004104163A2 WO2004104163A2 PCT/JP2004/007155 JP2004007155W WO2004104163A2 WO 2004104163 A2 WO2004104163 A2 WO 2004104163A2 JP 2004007155 W JP2004007155 W JP 2004007155W WO 2004104163 A2 WO2004104163 A2 WO 2004104163A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- sugar
- glycosylation
- reaction
- selective
- Prior art date
Links
- 238000006206 glycosylation reaction Methods 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims abstract description 55
- 230000013595 glycosylation Effects 0.000 title claims abstract description 15
- 235000000346 sugar Nutrition 0.000 claims abstract description 85
- 125000006239 protecting group Chemical group 0.000 claims abstract description 51
- 150000001720 carbohydrates Chemical group 0.000 claims abstract description 49
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 46
- 229930182470 glycoside Natural products 0.000 claims abstract description 18
- 150000002338 glycosides Chemical class 0.000 claims abstract description 18
- 230000001476 alcoholic effect Effects 0.000 claims abstract description 16
- 125000003396 thiol group Chemical group [H]S* 0.000 claims abstract description 15
- 150000008135 α-glycosides Chemical class 0.000 claims abstract description 11
- 150000002772 monosaccharides Chemical class 0.000 claims abstract description 9
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 8
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 8
- 150000002016 disaccharides Chemical class 0.000 claims abstract description 6
- 150000002402 hexoses Chemical class 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 61
- 238000006243 chemical reaction Methods 0.000 claims description 41
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical group ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 claims description 18
- -1 silylene group Chemical group 0.000 claims description 17
- 125000003277 amino group Chemical group 0.000 claims description 15
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 claims description 7
- 108010042833 7,8-diaminopelargonic acid aminotransferase Proteins 0.000 claims description 7
- 125000000524 functional group Chemical group 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- WQZGKKKJIJFFOK-DHVFOXMCSA-N L-galactose Chemical compound OC[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-DHVFOXMCSA-N 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 230000003029 glycosylic effect Effects 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 abstract description 5
- 239000000126 substance Substances 0.000 description 62
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 48
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- 239000000203 mixture Substances 0.000 description 25
- 102000003886 Glycoproteins Human genes 0.000 description 22
- 108090000288 Glycoproteins Proteins 0.000 description 22
- 238000003786 synthesis reaction Methods 0.000 description 22
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 238000004440 column chromatography Methods 0.000 description 18
- 238000004809 thin layer chromatography Methods 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 239000012156 elution solvent Substances 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000006188 syrup Substances 0.000 description 12
- 235000020357 syrup Nutrition 0.000 description 12
- 235000003332 Ilex aquifolium Nutrition 0.000 description 11
- 241000209027 Ilex aquifolium Species 0.000 description 11
- 238000012916 structural analysis Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 0 CC(OCC[C@@](C(*)C1OCc2ccccc2)OC(COC(C)=O)[C@@]1OCc1ccccc1)=O Chemical compound CC(OCC[C@@](C(*)C1OCc2ccccc2)OC(COC(C)=O)[C@@]1OCc1ccccc1)=O 0.000 description 6
- FOWDOWQYRZXQDP-UHFFFAOYSA-N adamantan-2-ol Chemical compound C1C(C2)CC3CC1C(O)C2C3 FOWDOWQYRZXQDP-UHFFFAOYSA-N 0.000 description 6
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 229960001153 serine Drugs 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical group N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 229930182830 galactose Natural products 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 108010070004 glucose receptor Proteins 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 229960002898 threonine Drugs 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 125000006627 ethoxycarbonylamino group Chemical group 0.000 description 2
- 150000002337 glycosamines Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 125000005524 levulinyl group Chemical group 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 150000003138 primary alcohols Chemical class 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GNIDSOFZAKMQAO-VIFPVBQESA-N (2s)-3-hydroxy-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 GNIDSOFZAKMQAO-VIFPVBQESA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- VWVRASTUFJRTHW-UHFFFAOYSA-N 2-[3-(azetidin-3-yloxy)-4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound O=C(CN1C=C(C(OC2CNC2)=N1)C1=CN=C(NC2CC3=C(C2)C=CC=C3)N=C1)N1CCC2=C(C1)N=NN2 VWVRASTUFJRTHW-UHFFFAOYSA-N 0.000 description 1
- WWSJZGAPAVMETJ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethoxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OCC WWSJZGAPAVMETJ-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- RBWNDBNSJFCLBZ-UHFFFAOYSA-N 7-methyl-5,6,7,8-tetrahydro-3h-[1]benzothiolo[2,3-d]pyrimidine-4-thione Chemical compound N1=CNC(=S)C2=C1SC1=C2CCC(C)C1 RBWNDBNSJFCLBZ-UHFFFAOYSA-N 0.000 description 1
- YVZYNXNBLFZJNU-ZHYIQUJTSA-N C(c1ccccc1)O[C@H](C1OC11)C2O[C@H]1OC2 Chemical compound C(c1ccccc1)O[C@H](C1OC11)C2O[C@H]1OC2 YVZYNXNBLFZJNU-ZHYIQUJTSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000006994 Koenigs-Knorr glycosidation reaction Methods 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 150000008550 L-serines Chemical class 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 229930182474 N-glycoside Natural products 0.000 description 1
- KWLCEFSFVXYXQE-HUJQZZBLSA-N N[C@@H](CO)C(=O)O.O[C@@H]1[C@H](N)[C@@H](O)[C@@H](O)[C@H](O1)CO Chemical compound N[C@@H](CO)C(=O)O.O[C@@H]1[C@H](N)[C@@H](O)[C@@H](O)[C@H](O1)CO KWLCEFSFVXYXQE-HUJQZZBLSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930182473 O-glycoside Natural products 0.000 description 1
- 150000008444 O-glycosides Chemical class 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- DIKJQUCPQSVKPE-UHFFFAOYSA-L [Ag+].[Ag+].OC([O-])=O.[O-]Cl(=O)(=O)=O Chemical compound [Ag+].[Ag+].OC([O-])=O.[O-]Cl(=O)(=O)=O DIKJQUCPQSVKPE-UHFFFAOYSA-L 0.000 description 1
- 150000003855 acyl compounds Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000007809 chemical reaction catalyst Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- JTGAUXSVQKWNHO-UHFFFAOYSA-N ditert-butylsilicon Chemical compound CC(C)(C)[Si]C(C)(C)C JTGAUXSVQKWNHO-UHFFFAOYSA-N 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 150000002256 galaktoses Chemical class 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002730 mercury Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 238000007344 nucleophilic reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 125000001557 phthalyl group Chemical group C(=O)(O)C1=C(C(=O)*)C=CC=C1 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- YMBCJWGVCUEGHA-UHFFFAOYSA-M tetraethylammonium chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC YMBCJWGVCUEGHA-UHFFFAOYSA-M 0.000 description 1
- ISXOBTBCNRIIQO-UHFFFAOYSA-N tetrahydrothiophene 1-oxide Chemical compound O=S1CCCC1 ISXOBTBCNRIIQO-UHFFFAOYSA-N 0.000 description 1
- 150000004072 triols Chemical class 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 150000008136 β-glycosides Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to an ⁇ -selective glycosylation reaction method, and more specifically, a galactatose or other sugar structure having a certain basic structure or a derivative compound thereof, or a bran structure or a derivative compound thereof at a reducing end. Oligo sugar is more than disaccharide!
- the present invention relates to a method for selective glycosylation of glycans. Background art
- sugar-containing macromolecules present as extracellular membrane components and extracellular molecules in higher organisms, have been attracting attention in relation to their functions in vivo.
- a typical example of the sugar chain polymer is glycoprotein.
- glycoproteins With a few exceptions, most of the cell surface large serum proteins in many animals, including humans, are glycoproteins. Antibodies, receptors, hormones, enzymes, etc. are often glycoproteins rather than simple proteins. In the past, many of the functions of these glycoproteins in vivo were explained solely by the protein structure alone. However, since the discovery that the specificity of the ABO ( ⁇ ) blood group antigen was determined by the subtle differences in the structure of the glycosyl moiety, it was necessary to establish and maintain multicellular organisms. In various discriminating phenomena, the role of sugar chains as signals in glycoproteins has been increasingly highlighted.
- glycosylation is extremely specific to the function of the protein itself. Selectivity is given.
- sugar chains for example, cancer-specific antibodies derived from sugar chains
- Hara's research the analysis of the sugar chain structure (its sequence and tertiary structure) has been dramatically advanced.
- Glycoprotein sugar chains are composed of N-glycoside-linked form (Asn-linked form) linked to L-asparagine, an amino acid residue constituting the polypeptide, and O-glycoside-linked form (L-serine or L-threonine). (Combined type).
- O-linked sugar chains are found in a wide range of mucus proteins, serum proteins, membrane proteins and the like.
- Such O-linked sugar chains form a mono-O-glycosidic bond by a nucleophilic reaction using N-acetyl-D-galatatosamine as a donor and an alcoholic hydroxyl group of L-serine or L-threonine as an acceptor. Things are typical.
- bran protein as a sample, for example, micrograms or more It is necessary to prepare for quantity. However, it is not easy to prepare a necessary amount of glycoprotein sample because the target glycoprotein is usually present in an extremely small amount of nanogram / milliliter order in animal or plant tissues or cells.
- An object of the present invention is to enable a highly selective ⁇ -glycosylation reaction in a certain saccharide structure, including the chemical synthesis of a ⁇ -linked glycoprotein, by a simple and convenient means. Disclosure of the invention
- the inventor of the present application has found that a highly selective ⁇ -glycosylation reaction on a sugar chain receptor can be caused only by forming a protective group having a silyl acetal structure on a certain hydroxyl group in a sugar structure such as galactose. I found it.
- the first invention of the present application is a method for performing a glycosylation reaction between a sugar structure as a donor and an alcoholic hydroxyl group or a thiol group of an acceptor compound,
- the saccharide structure is a monosaccharide or a disaccharide or higher oligosaccharide or a hexose or higher saccharide structure that is a reducing terminal of a sugar chain, and at least the 4th and 6th positions have water.
- a compound having an acid group and satisfying the structural conditions that the hydroxyl group at the 4-position is in the axianole orientation and the group at the 5-position is the equatorial orientation
- the protecting group having a silyl acetal structure is formed cyclically over the hydroxyl group at the 4-position and the 6-position of the predetermined saccharide structure, and the alcohol of the lacceptor compound is formed.
- a highly selective ⁇ -Dalikosylic reaction can be caused by a very simple means of performing a Dalikosyridani reaction with a hydroxyl group or a thiol group.
- the ratio of ⁇ -anomers in the resulting daricoside is generally at least 80%.
- This ⁇ -selective glycosylation method does not interfere with the glycosylation reaction of the ⁇ -acetylamino group, which has been a problem in the chemical synthesis of ⁇ -linked glycoproteins, as described later. Furthermore, the operation is extremely simple compared to the prior art proposed from the same viewpoint, for example, the above-mentioned method using a 2-azide derivative by Paulsen et al., And the improved method by Ferrari and Pavia. Versatility This is a chemical synthesis method. Therefore, it has become possible to prepare a glycoprotein as a research sample in the case of studying and analyzing glycoprotein sugar chains and lectins by simple chemical synthesis.
- the monoselective glycosylation method of the first invention is generally established between a saccharide structure (donor) having predetermined conditions and an receptor compound having at least an alcoholic hydroxyl group or a thiol group, It is not limited to the synthesis of o-linked glycoprotein as described above. That is, the donor may be a monosaccharide or an oligosaccharide, and the amino acid, the peptide chain, the monosaccharide, the sugar chain, and other types as long as the acceptor compound has an alcoholic hydroxyl group or a thiol group. Any organic compound can be used.
- the saccharide structure according to the first invention is any one of the following (a) to (d).
- the saccharide structure as a donor needs to satisfy certain structural conditions described in the first invention.
- Any of the saccharide structures listed in (a) to (d) of the second invention can be exemplified.
- the saccharide structure according to the first invention or the second invention has a C 1 conformation (ie, “ 4 CL” viranoside structure) in the D form, and 1 in the L form. It is in the C conformation (ie, the “'C 4 ” viranoside structure).
- the donor saccharide structure is particularly preferred because the C-conformation of the D-form saccharide structure and the 1C-conformation of the saccharide structure of the S-L form are the preferred conformations, respectively.
- the protective group having a silyl acetal structure according to any one of the first to third inventions is a dialkylsilylene group.
- the cyclic protective group formed over the hydroxyl groups at the 4- and 6-positions of the saccharide structure is not limited as long as it has a silyl acetal structure. More preferably, it can form a dialkylsilylene group.
- the dialkylsilylene group according to the fourth invention is a di-butyl) monosilylene group (DTBS group).
- the dialkylsilylene group is particularly preferably a di (t-butyl) -silylene group (DTBS group).
- a protective group modification is performed on a predetermined reactive functional group in the saccharide structure in advance.
- Performing a certain protective group modification as in the sixth invention is effective in forming the protective group of the silyl acetal structure in the saccharide structure or in the subsequent selective glycosylation reaction, and is effective in suppressing unnecessary side reactions. It is.
- the protecting group for the amino group is a 2,2,2-trichloroethoxycarbonyl group (Troc group).
- the saccharide structure has an amino group (particularly at the 2-position)
- a phthalyl group (Phth group)
- Phth groups have poor introduction efficiency and are not suitable for large-scale synthesis.
- hydrazine is generally used for deprotection of the Phth group, and therefore, in order to avoid formation of amides due to attack on the methyl ester.
- the methyl ester is removed, and the free carboxylic acid is methyl esterified again.
- the saccharide structure according to any one of the first invention to the seventh invention has a substituent at the 2-position which interferes with the selective glycosylation reaction by participation of an adjacent group. It is.
- one of the particularly advantageous effects is that a sugar having a substituent at the 2-position that strongly interferes with the monoselective glycosylation reaction due to participation of an adjacent group in a normal glycosylation reaction.
- a highly selective ⁇ -glycosylation reaction can be ensured.
- the 2-position substituent according to the eighth invention is an amino group bonded to a trocetyl group of Troc group.
- the substituent at the 2-position of the saccharide structure is an amino group bonded to a Troc group acetyl group (including a case where the saccharide structure is modified with the Troc group acetyl group according to the sixth and seventh inventions).
- a Troc group acetyl group including a case where the saccharide structure is modified with the Troc group acetyl group according to the sixth and seventh inventions.
- this has been a major obstacle in the chemical synthesis of O-linked glycoproteins. Therefore, in such a case, the advantage of performing the ⁇ -selective dalycosylation reaction method of the first invention is particularly large.
- the receptor compound according to any one of the first invention to the ninth invention contains an amino acid having an alcoholic hydroxyl group or a thiol group, and any one of these amino acids as a constituent residue.
- Peptide chains, monosaccharides, or oligosaccharides or sugar chains of two or more sugars are used.
- the acceptor compound used in the monoselective glycosylation reaction method is not limited as long as it has an alcoholic hydroxyl group or a thiol group, and any of the compounds specified in the tenth invention can be preferably exemplified.
- FIG. 1 is a diagram showing a flow of a method for one-selective glycosylation according to the prior art.
- Fig. 2 shows the flow of the conventional selective glycosylation reaction method.
- FIG. FIG. 3 is a diagram showing an ⁇ -selective glycosylation reaction according to an example of the present invention.
- the ⁇ -selective glycosylation reaction method of the present invention is a method in which a glycosylation reaction is carried out between a sugar structure (sugar donor) and a compound having an alcoholic hydroxyl group or thiol group (sugar acceptor). .
- the feature is that a glycosylation reaction is performed between an acyl compound and a cyclic compound with a cyclic silyl acetal structure protecting group formed over the hydroxyl groups at positions 4 and 6 of the sugar structure.
- a highly ⁇ -selective glycosylation reaction method in which a-daricoside is contained at a ratio of 80% or more in the a / jS ratio among the obtained saccharide daricosides is possible.
- a certain reactive functional group other than the hydroxyl group at the 4-position and the 6-position in the saccharide structure may be modified with the protective group in advance, as described in the ⁇ Function and Effect of the Eighth Invention '' section. It is preferred for various reasons mentioned above.
- the type of the reactive functional group to be modified with the protective group and the position in the sugar structure in advance are not limited, and the protective group may be appropriately modified as necessary, but the amino group or hydroxyl group at the 2-position of the sugar structure, Representative examples of protecting group modification for the hydroxyl group at position 3 can be exemplified.
- Examples of the protecting group for the amino group at the 2-position include general protecting groups such as acetyl group, trihaloacetyl group, levulinyl group, phthaloyl group and Troc group.
- Examples of the protecting group for the hydroxyl group at the 2-position include all acetyl protecting groups such as an acetyl group, a monohaloacetyl group, a dihaloacetyl group, a levulinyl group, a benzoyl group, and a bivaloyl group.
- Examples of the protective group for the hydroxyl group at the 3-position include an acetyl group, a benzoyl group, an acyl group such as a bivaloyl group, and an ether group such as a benzyl group, a p-methoxybenzyl group, and an aryl group. be able to.
- the protecting groups for the amino or hydroxyl group at the 2-position show strong adjacent group involvement in the ordinary glycosylation reaction, and are important for ⁇ -selective daricosylation reaction. However, there is no such concern in the a-selective glycosylation reaction method according to the present invention as described above.
- the reaction conditions, the concentrations of the donor and the acceptor in the reaction system, the use of the reaction catalyst, and the like are not particularly limited, and may be appropriately designed as necessary. Can be.
- a non-polar solvent such as methylene chloride
- the reaction can be performed at a temperature in the range of 130 ° C. to 0 ° C.
- the concentration of the donor and the receptor in the reaction system is preferably set to about 0.1 M.
- the concentration ratio between the donor and the acceptor in the reaction system may be basically determined stoichiometrically, but more preferably, about 1.5 equivalents of donor per acceptor may be used.
- the saccharide structure used in the present invention has at least hydroxyl groups at the 4- and 6-positions, and at least 6-carbon sugar that satisfies the structural condition that the hydroxyl group at the 4-position is axial and the group at the 5-position is equatorial. It is a sugar structure.
- the saccharide structure can be used as a monosaccharide or as a reducing end of an oligosaccharide or a sugar chain of a disaccharide or more.
- the type of the bran structure is not limited as long as it corresponds to the above, but any of the following (a) to (d) can be typically exemplified.
- Each of these concepts is a concept including a derivative in which an arbitrary substituent is introduced at an arbitrary position, for example, a substituent derivative such as N-acetylgalactosamine in D / L-galactose.
- these saccharide structures Is a 1 C conformation of a six-membered ring (X C 4 Biranoshido structure) in preferably C 1 conformation of a six-membered ring (4 C, Biranoshido structure), L body in D form
- X C 4 Biranoshido structure a six-membered ring
- a six-membered ring 4 C, Biranoshido structure
- the cyclic protecting group formed over the hydroxyl groups at the 4- and 6-positions of the saccharide structure is not limited as long as it has a silyl acetal structure, but is particularly preferably a dialkylsilylene group, especially a di (t-butyl) monosilyl group.
- a len group (DTBS group) can be preferably exemplified.
- a diisopropyl-silylene group, a dibutyl-silylene group, a di-n-butyl-silylene group, a di-n-propyl-silylene group, and the like can be preferably exemplified.
- the sceptor compound used in the present invention may be basically an organic compound having an alcoholic hydroxyl group or a thiol group.
- Preferred examples of the acceptor compound include an amino acid having an alcoholic hydroxyl group or a thiol group, such as serine, threonine, and cysteine. Since the present invention is a kind of organic synthesis method, it is needless to say that both L-amino acids and D-amino acids can be used.
- a peptide chain (oligopeptide or polypeptide) containing any one of the above amino acids as a constituent residue can also be preferably exemplified as the acceptor compound.
- Monosaccharides, two or more oligosaccharides, and sugar chains are also preferably exemplified.
- sialic acid dimer of the following formula 1 obtained from colominic acid
- its carboxyl group was methylesterified to obtain the sialic acid dimer represented by the formula 2 below.
- the carboxyl group at the non-reducing end formed a lactone with the hydroxyl group at the 8-position at the reducing end.
- disialyl galactose represented by the following chemical formula 3 was obtained.
- “Ac” means an acetyl group
- SPh means a phenylthio group.
- the a isomer shown in Chemical Formula 5 is 2- (trimethylsilyl) ethyl [methyl 5-acetamido 8-O- (5-acetamido 4,7,8,9-tetra-O-acetyl-1,3,5-dideoxy-D —Glycerol oj—D—Galactor 2-nonuropylanoshirono-1 ', 9-lactone) 1,4,7-Di0-acetyl-1,3,5-dideoxy-1D—Glycete 1 ⁇ —D—Galacto-2-no Nurovirano silonate] 1 (2 ⁇ 3) 1 2,6-di-benzyl-galactopyranoside.
- the galactosamine mint triol derivative has a "4 d" Biranoshi de structure.
- DTBS (OT f) 2 in which di-t-butylsilane was added with trifluoromethanesulfonic acid as a leaving group was used to prepare 4, 6 DTBS was introduced at the 1-position to obtain a compound having a protecting group having a silyl acetal structure at the 4- and 6-positions and represented by the following formula (7).
- TrocC1 was allowed to act on the compound represented by the chemical formula 7 in a pyridine solvent to obtain a compound represented by the following chemical formula 8 in which a Troc group was introduced at the 3-position.
- This formula 8 was used as the sugar structure (galatatosamine donor) used in the method for selective glycosylation reaction according to the present invention.
- the compound represented by the chemical formula 8 is phenyl 2-deoxy-4,6-O-di-tert-butylsilylene-11-thio-13-O— (2,2,2-trichloromouth ethoxycanolebonyl) -2- (2,2, 2-Trichloro mouth ethoxycarbonylamino) 1] 3-D is galactopyranoside.
- a glycoside represented by the following formula 9 was obtained from the saccharide structure represented by the chemical formula 8 and the receptor compound represented by the chemical formula 5 by the following process.
- the glycoside represented by Chemical Formula 9 is 2- (trimethylsilyl) ethyl [methyl 5-acetamido 8_ ⁇ _ (5-acetamido) 4,7,8,9-tetra-10-acetyl-13,5_dideoxy-1 D-glyceride Mouth a— D—Galacto 2—Nonylobiranoshirono 1,1,, 9—Rataton) 1,4,7—Di-1—Acetyl-3,5-dideoxy _D—Glycee ⁇ —D—Galacto 1-2—Nonulo Vilanoshironate-1 (2 ⁇ 3)]-1 [2-Doxy-4,6-O-di-tert-butylsilylene-1 3-0- (2,2,2-trichloromouth ethoxycarbonyl) 1 2 (2,2,2 2-Trichloromouth ethoxycarbonylamino) ⁇ -D-galatatopyranosyl] 1,2,6-di-benzy ⁇ ⁇
- the saccharide structure (118 mg, 0.155 mmo 1) represented by the chemical formula 8 and the receptor compound (10 Omg, 77.4 mo 1) represented by the chemical formula 5 were combined with 5.0 m 1 Was dissolved in dichloromethane, MS 4A (20 Omg) was added, and the mixture was stirred at room temperature for 1 hour. Then 0. Cool to C and add 70 mg or 0.310 mmol of N-iodinated succinimide (NIS) and 2.1 or 31.11 ⁇ 1 1 of trifluoromethanesulfonic acid (T f OH). Stirred.
- NIS N-iodinated succinimide
- T f OH trifluoromethanesulfonic acid
- this glycoside was subjected to structural analysis (by NMR, the same applies hereinafter), about 8% of i3-glycoside was found, but ⁇ -glycoside was obtained in a yield of 85%.
- glucose primary alcohol
- chemical formula 11 which is a primary alcohol
- a sugar structure donor is introduced into the 6-position hydroxyl group as follows. Tried.
- the Troc group which was the 3-position protecting group in the saccharide structure of Formula 8 was replaced with the same acetyl group of the same acyl group.
- the introduction of the sugar structure donor into the 6-position hydroxyl group of the glucose receptor of the same chemical formula 11 as in Example 5 was carried out as follows. Tried.
- the sugar structure of formula 14 (1.10 g, 1.93 mmo 1) and the compound of formula 5 (1.00 g, 0.774 mmo 1), which is an acceptor compound, are After dissolving in 1 of dichloromethane and adding MS 4A (2 g), the mixture was stirred at room temperature for 1 hour. Thereafter, the mixture was cooled to 0 ° C., NIS (886 mg, 3.86 mmol) and TfOH (34 ⁇ I, 0.386 mmol) were added, and the mixture was stirred for 1 hour.
- the formed solid was filtered off through celite and washed with chloroform. Then diluted with black port Holm combined with the filtrate and washes, and the organic layer sat. N a 2 CO 3, sat. And washed with N a 2 S 2 0 3, the order of B rine, N a 2 SO After drying and concentrating in step 4 , the obtained syrup was subjected to column chromatography.
- the type of the protecting group at the 3-position in the saccharide structure is not an element that determines whether or not the ⁇ - selective glycosylation reaction can be performed.
- the total amount or almost all of the dalicoside produced in each of the above examples was ⁇ -glycoside, whereas, as in Comparative Example 1, the silyl acetal structure was distributed over the hydroxyl groups at the 4- and 6-positions. Only when a sugar structure donor having no protecting group was used, the total amount of glycosides produced was] 3-glycoside. Therefore, the factor that determines whether or not the monoselective glycosylation reaction according to the present invention is possible is that the protective group having a silyl acetal structure is formed in a cyclic manner over the hydroxyl groups at the 4- and 6-positions of the sugar structure donor. That ".
- Example 7 Involvement of neighboring group of 2-position protecting group in amino bran donor (1)
- the compound of the following formula 16 in which the 2-position Troc group in the compound of the formula 8 is changed to a Bz group is used as a sugar structure donor.
- a sugar structure donor As described in Example 5, an attempt was made to introduce a sugar structure donor into the 6-position hydroxyl group of the glucose receptor of the same chemical formula 11 as in Example 5.
- the sugar structure of Formula 16 (50 mg, 80.5 ⁇ 1) and the compound of Formula 11 (47 mg, 0.12 lmmo 1), which is one compound of the ceptor, are dissolved in 2 mL of dichloromethane. After adding MS 4A (10 Omg), the mixture was stirred at room temperature for 1 hour. Thereafter, the mixture was cooled to 0 ° C., NIS (36 mg, 0.161 mmol) and TfOH (1 ⁇ I, 16.1 mol) were added, and the mixture was stirred for 20 hours.
- Example 8 Involvement of Adjacent Group of 2-position Protecting Group in Amino Sugar Donor (2) For the same reason as in Example 7, it was a protecting group for the 2-position amino group in the sugar structure shown in Chemical Formula 8. Troc groups are clearly more involved in neighboring groups
- the compound of Formula 18 below which was changed to a recognized Phth group (actually, the Troc group at the 3-position was also changed to an acetyl group), was used as a sugar structure donor, and as described in Example 5, An attempt was made to introduce a sugar structure donor into the 6-position hydroxyl group of the glucose receptor of the same chemical formula 11.
- the saccharide structure of Formula 18 (100 mg, 0.17 Immo 1) and the compound of Formula 11 (10 Omg, 0.256 mmo 1), which is a single sceptor compound, are dissolved in 4.3 ml of dichloromethane, and MS4A (20 Omg) After the addition, the mixture was stirred at room temperature for 1 hour. Thereafter, the mixture was cooled to 0 ° C., NIS (77 mg, 0.342 mmo 1) and ⁇ f OH (3 ⁇ 1, 34.2 m ⁇ 1) were added, and the mixture was stirred for 30 minutes.
- Example 9 Synthesis of Hi-galactosamine-serine
- the most useful case of the one-selective glycosylation reaction in a galactose-type sugar structure donor is the chemical synthesis of an O-linked sugar chain. Therefore, the latter case is selected from a-galactosamine-l-serine or mono-galactosamine-l-threonine, which constitutes the binding site between the sugar chain and the peptide in the O-linked sugar chain, and the following case is selected.
- Monoselective glycosylation Tried the law.
- a saccharide structure of Formula 8 with a Troc group introduced at the 3-position was used in consideration of subsequent sugar chain elongation.
- two types of serine having a protective group introduced were prepared as shown in Chemical Formula 20 and Chemical Formula 21.
- a saccharide structure of Formula 8 (122 mg, 0.16 Ommo 1) and an aceceptor compound of Formula 20 (N-benzyloxycarbonyl-L-serine. 1 pentafluorophenylinoleester; 50 mg, 0.123 mmo 1 ) was dissolved in 2.8 ml of dichloromethane, and MS4A (17 Omg) was added. And stirred for 1 hour. Then, the mixture was cooled to 0 ° C., NIS (72 mg, 0.320 mmol) and Tf ⁇ H (2.8 ⁇ l, 32.0 ⁇ 1) were added, and the mixture was stirred for 30 minutes.
- NIS 72 mg, 0.320 mmol
- Tf ⁇ H 2.8 ⁇ l, 32.0 ⁇ 1
- a saccharide structure of formula 8 (100 mg, 0.13 lmmo 1) and a compound of formula 21 (N-9-fluorenylmethoxycarbol-L-serine-1-pentafrenololo) Phenylestenole; 5 Omg, 0.11 mmo 1) was dried in 2.3 ml of dichloromethane, MS 4A (15 Omg) was added, and the mixture was stirred at room temperature for 1 hour. did. Then, the mixture was cooled to 0 ° C., NIS (59 mg, 0.262 mmol) and TfOH (2.3 ⁇ l, 26.2 umo 1) were added, and the mixture was stirred for 30 minutes.
- saccharide structure mouth 150mg, 0.223mm o 1
- 2-Adamantanol (22.6mg, 0.148mm o l) were dissolved in 3.7ml of dichloromethane with MS4A (17 Omg). It was added and cooled to 0 ° C after stirring for 1 hour at room temperature, S nC 1 2 in the dark (42 ⁇ 3mg, 0. 223 mm o 1), a g C 10 4 (55. 5mg, 0. 267mm o 1) was added and stirred for 16 hours.
- a highly selective ⁇ -daricosylation reaction in a saccharide structure can be achieved by a simple and convenient method.
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/555,565 US8148505B2 (en) | 2003-05-22 | 2004-05-19 | Method of α-selective glycosylation |
JP2005506388A JP4599295B2 (ja) | 2003-05-22 | 2004-05-19 | α−選択的グリコシル化反応方法 |
EP04733984A EP1626053B1 (en) | 2003-05-22 | 2004-05-19 | Method of alpha-selective glycosylation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-144622 | 2003-05-22 | ||
JP2003144622 | 2003-05-22 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2004104163A1 WO2004104163A1 (ja) | 2004-12-02 |
WO2004104163A2 true WO2004104163A2 (ja) | 2004-12-02 |
WO2004104163A3 WO2004104163A3 (ja) | 2005-02-24 |
Family
ID=33475213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/007155 WO2004104163A2 (ja) | 2003-05-22 | 2004-05-19 | α−選択的グリコシル化反応方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8148505B2 (ja) |
EP (1) | EP1626053B1 (ja) |
JP (1) | JP4599295B2 (ja) |
CN (1) | CN100384862C (ja) |
WO (1) | WO2004104163A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006335644A (ja) * | 2005-05-31 | 2006-12-14 | Gifu Univ | エンドα−ガラクトサミニダーゼ高感度基質、その製造方法及び利用方法 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI418563B (zh) * | 2011-12-16 | 2013-12-11 | Univ Nat Chiao Tung | α-選擇性醣基化反應之方法 |
CN107001528A (zh) | 2014-07-09 | 2017-08-01 | 米德瑞(美国)有限公司 | 低聚糖组合物及其制备方法 |
CA2975095A1 (en) | 2015-01-26 | 2016-08-04 | Cadena Bio, Inc. | Oligosaccharide compositions for use as animal feed and methods of producing thereof |
CN116270718A (zh) | 2015-04-23 | 2023-06-23 | Dsm营养产品有限责任公司 | 聚糖治疗剂和治疗方法 |
WO2017083520A1 (en) * | 2015-11-13 | 2017-05-18 | Cadena Bio, Inc. | Animal therapeutic and feed compositions and methods of use |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0570471A (ja) * | 1991-09-12 | 1993-03-23 | Asahi Chem Ind Co Ltd | グリコシル化法 |
US5371210A (en) | 1992-06-22 | 1994-12-06 | Eli Lilly And Company | Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
CN1040114C (zh) * | 1992-06-22 | 1998-10-07 | 伊莱利利公司 | 立体选择性糖基化方法 |
UA41261C2 (uk) * | 1992-06-22 | 2001-09-17 | Елі Ліллі Енд Компані | Спосіб одержання збагачених бета-аномером нуклеозидів |
US5527891A (en) * | 1994-03-09 | 1996-06-18 | Biomira, Inc. | Stereodirected process for synthesis of α-N-acetylgalactosaminides |
JPH09286793A (ja) * | 1996-04-17 | 1997-11-04 | Sumitomo Pharmaceut Co Ltd | 環状シリルエーテル型保護基を用いたグリコシル化合物の製造方法 |
-
2004
- 2004-05-19 CN CNB2004800140567A patent/CN100384862C/zh not_active Expired - Fee Related
- 2004-05-19 JP JP2005506388A patent/JP4599295B2/ja not_active Expired - Fee Related
- 2004-05-19 US US10/555,565 patent/US8148505B2/en not_active Expired - Fee Related
- 2004-05-19 EP EP04733984A patent/EP1626053B1/en not_active Not-in-force
- 2004-05-19 WO PCT/JP2004/007155 patent/WO2004104163A2/ja active Application Filing
Non-Patent Citations (2)
Title |
---|
None |
See also references of EP1626053A4 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006335644A (ja) * | 2005-05-31 | 2006-12-14 | Gifu Univ | エンドα−ガラクトサミニダーゼ高感度基質、その製造方法及び利用方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100384862C (zh) | 2008-04-30 |
JP4599295B2 (ja) | 2010-12-15 |
JPWO2004104163A1 (ja) | 2006-07-20 |
EP1626053A2 (en) | 2006-02-15 |
CN1795199A (zh) | 2006-06-28 |
EP1626053A4 (en) | 2007-05-02 |
WO2004104163A3 (ja) | 2005-02-24 |
US20060122379A1 (en) | 2006-06-08 |
EP1626053B1 (en) | 2011-07-06 |
US8148505B2 (en) | 2012-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Barresi et al. | The synthesis of β-mannopyranosides by intramolecular aglycon delivery: scope and limitations of the existing methodology | |
Codée et al. | Chemoselective glycosylations using sulfonium triflate activator systems | |
US4362720A (en) | Synthesis of 2-amino-2-deoxyglycoses and 2-amino-2-deoxyglycosides from glycals | |
US4308376A (en) | Synthesis of 2-amino-2-deoxyglycoses and 2-amino-2-deoxyglycosides from glycals | |
Reina et al. | Rapid and efficient synthesis of α (1–2) mannobiosides | |
WO1998038197A1 (en) | Protected aminosugars | |
WO2004104163A2 (ja) | α−選択的グリコシル化反応方法 | |
Hashihayata et al. | Convergent total syntheses of oligosaccharides by one-pot sequential stereoselective glycosylations | |
Lafont et al. | A convenient access to β-glycosides of N-acetyllactosamine | |
de La Cruz et al. | Influence of the reducing-end anomeric configuration of the Man 9 epitope on DC-SIGN recognition | |
Zhu et al. | A facile regio-and stereoselective synthesis of mannose octasaccharide of the N-glycan in human CD2 and mannose hexasaccharide antigenic factor 13b | |
Mannino et al. | Hydrogen-bond-mediated aglycone delivery (HAD) and related methods in carbohydrate chemistry | |
Popelová et al. | A concise synthesis of 4-nitrophenyl 2-azido-2-deoxy-and 2-acetamido-2-deoxy-D-mannopyranosides | |
Takatani et al. | Synthesis of N-linked pentasaccharides with isomeric glycosidic linkage | |
Figueroa-Pérez et al. | Synthesis of a sialyl-α-(2→ 6)-lactosamine trisaccharide with a 5-amino-3-oxapentyl spacer group at C-1I | |
Lee et al. | A comparative study of different glycosylation methods for the synthesis of d-mannopyranosides of Nα-fluorenylmethoxycarbonyl-trans-4-hydroxy-l-proline allyl ester | |
Hada et al. | Stereoselective synthesis of 1, 2-cis galactosides: synthesis of a glycolipid containing Galα1-6Gal component from Zygomycetes species | |
Jaiswal et al. | Recent advances in stereoselective intramolecular O-glycosylation | |
Traboni et al. | Adaptation of Zemplén's conditions for a simple and highly selective approach to methyl 1, 2− trans glycosides | |
Cruz et al. | Influence of the reducing-end anomeric configuration of the Man9 epitope on DC-SIGN recognition | |
Cruz Ruiz et al. | Influence of the reducing-end anomeric configuration of the Man9 epitope on DC-SIGN recognition | |
JPH0195A (ja) | α−グリコシルセラミド誘導体 | |
CA1111417A (en) | Synthesis of 2-amino-2-deoxyglycoses and 2-amino-2- deoxyglycosides from glycals | |
JPH03264595A (ja) | 新規なグリコシル化方法 | |
CA1111418A (en) | Synthesis of 2-amino-2-deoxyglycoses and 2-amino-2- deoxyglycosides from glycals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005506388 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004733984 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048140567 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2006122379 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10555565 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2004733984 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10555565 Country of ref document: US |